Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Erratum for Laporte-Amargos et al., "Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia".

Antimicrobial agents and chemotherapy·2026
Same author

Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial.

HemaSphere·2026
Same author

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Bone marrow transplantation·2026
Same author

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer·2026
Same author

Autologous and allogeneic haematopoietic cell transplantation in adult patients with Hodgkin lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee and Lymphoma Working Party.

The Lancet. Haematology·2026
Same author

CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis.

Science translational medicine·2026

相关实验视频

Updated: Jul 27, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K

免疫效应细胞相关的血液毒性:EHA/EBMT共识分级和最佳实践建议

Kai Rejeski1, Marion Subklewe1, Mahmoud Aljurf2

  • 1Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

Blood
|June 10, 2023
PubMed
概括

血液毒性是CAR T细胞治疗的常见副作用. 这一共识为分类和管理免疫效应细胞相关血毒性 (ICAHT) 提供了一个框架,以改善患者的治疗结果.

更多相关视频

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

487
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.2K

相关实验视频

Last Updated: Jul 27, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.5K
In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

487
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.2K

科学领域:

  • 血液学 血液学 血液学
  • 免疫治疗是一种免疫疗法.
  • 在瘤学瘤学.

背景情况:

  • 血液毒性,包括细胞衰竭,是化学抗原受体 (CAR) T 细胞治疗后最常见的不良事件,导致严重的感染风险.
  • 现有的管理CAR-T细胞治疗相关的血液毒性的实践在全球范围内显示出相当大的异质性.
  • 需要标准化指导方针来解决免疫效应细胞相关血毒性 (ICAHT) 的分级和管理问题.

研究的目的:

  • 在CAR T细胞治疗后对免疫效应细胞相关血毒性 (ICAHT) 的分级和管理达成共识.
  • 为这种特定的毒性制定标准化最佳实践建议.
  • 引入ICAHT作为一个独立的毒性类别.

主要方法:

  • 这是欧洲血液和骨髓移植学会 (EBMT) 和欧洲血液学会 (EHA) 的联合倡议.
  • 涉及36名CAR T细胞专家的国际小组参加虚拟会议和为期两天的会议.
  • 根据专家审议和文献审查,制定了建议.

主要成果:

  • 创建了一个分类系统来对ICAHT进行分级,该分类系统基于中性质衰竭的深度和持续时间 (早期和晚期).
  • 建议涵盖风险因素,输注前评分系统 (例如CAR-HEMATOTOX),诊断工作和血细胞瘤的识别.
  • 制定了管理ICAHT的共识指南,包括生长因子支持,抗感染预防,输血和干细胞干预.

结论:

  • 免疫效应细胞相关血毒性 (ICAHT) 被提出作为免疫效应细胞治疗后的一个独特的毒性类别.
  • 建立了评级ICAHT的框架,包括风险因素评估和诊断工作.
  • 专家建议为ICAHT的短期和长期管理提供了全面的方法,旨在标准化护理并提高患者安全.